Design and synthesis of rho kinase inhibitors (III)

被引:42
作者
Iwakubo, Masayuki
Takami, Atsuya
Okada, Yuji
Kawata, Takehisa
Tagami, Yoshimichi
Sato, Motoko
Sugiyama, Terumi
Fukushima, Kayoko
Taya, Shinichiro
Amano, Mutsuki
Kaibuchi, Kozo
Iijima, Hiroshi
机构
[1] Kirin Brewery Co Ltd, Pharmaceut Res Labs, Gunma 3701295, Japan
[2] Nagoya Univ, Grad Sch Med, Dept Cell Pharmacol, Aichi 4668550, Japan
关键词
rho kinase; inhibitor; structure-activity relationship; myosin-binding subunit phosphorylation;
D O I
10.1016/j.bmc.2006.10.028
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The structure-activity relationship of Rho kinase inhibitors bearing an isoquinoline scaffold was studied. N-(1-Benzyl-3-pyrrolidyl)-N-(5-isoquinolyl)amine analogues were optimized with respect to their inhibitory potencies for the enzyme and for chemotaxis. The potent analogues were further evaluated by an ex vivo test in which the selected compounds were orally administered to rats, and the Rho kinase inhibitory potency observed in the rat serum was evaluated 3 h after the administration. Compound 23g showed a high level of Rho kinase inhibitory activity in the rat serum and was stable in an in vitro metabolic test using a microsomal cytochrome preparation. The (R)-isomer of 23g displayed a higher level of inhibitory potency than the (S)-isomer in a cell-free kinase assay and in the cell migration assay (IC50ENZ = 25 nM and IC50MCP = 1 mu M). The (R)-isomer successfully inhibited the phosphorylation of MBS (myosin-binding subunit) in cells. (c) 2006 Published by Elsevier Ltd.
引用
收藏
页码:1022 / 1033
页数:12
相关论文
共 26 条
[1]   Protein kinase a in complex with rho-kinase inhibitors Y-27632, fasudil, and H-1152P: Structural basis of selectivity [J].
Breitenlechner, C ;
Gassel, M ;
Hidaka, H ;
Kinzel, V ;
Huber, R ;
Engh, RA ;
Bossemeyer, D .
STRUCTURE, 2003, 11 (12) :1595-1607
[2]   Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway [J].
Chitaley, K ;
Wingard, CJ ;
Webb, RC ;
Branam, H ;
Stopper, VS ;
Lewis, RW ;
Mills, TM .
NATURE MEDICINE, 2001, 7 (01) :119-122
[3]   Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells [J].
Fukata, Y ;
Amano, M ;
Kaibuchi, K .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2001, 22 (01) :32-39
[4]  
HARTWIG JF, 2003, MODERN AMINATION MET
[5]  
Honjo M, 2001, INVEST OPHTH VIS SCI, V42, P137
[6]   Rho kinase as potential therapeutic target for cardiovascular diseases: opportunities and challenges [J].
Hu, E ;
Lee, D .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2005, 9 (04) :715-736
[7]   Y-27632, an inhibitor of Rho-associated protein kinase, suppresses tumor cell invasion via regulation of focal adhesion and focal adhesion kinase [J].
Imamura, F ;
Mukai, M ;
Ayaki, M ;
Akedo, H .
JAPANESE JOURNAL OF CANCER RESEARCH, 2000, 91 (08) :811-816
[8]  
Ishizaki T, 2000, MOL PHARMACOL, V57, P976
[9]   Design and synthesis of Rho kinase inhibitors (II) [J].
Iwakubo, Masayuki ;
Takami, Atsuya ;
Okada, Yuji ;
Kawata, Takehisa ;
Tagami, Yoshimichi ;
Ohashi, Hiroshi ;
Sato, Motoko ;
Sugiyama, Terumi ;
Fukushima, Kayoko ;
Iijima, Hiroshi .
BIOORGANIC & MEDICINAL CHEMISTRY, 2007, 15 (01) :350-364
[10]   The structure of dimeric ROCK I reveals the mechanism for ligand selectivity [J].
Jacobs, M ;
Hayakawa, K ;
Swenson, L ;
Bellon, S ;
Fleming, M ;
Taslimi, P ;
Doran, J .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (01) :260-268